ABSTRACT INTRODUCTION
INTRODUCTION
The diagnosis and classification of myelodysplastic syndromes (MDS) always remained a challenge over past several decades. 1 MDS can be defined as a group of several conditions characterized by clonal stem cell disorder that manifests dysplastic and ineffective blood cell production compounded by a variable risk of transformation to acute Ghosh A 1 1 
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leukemia. [2] [3] [4] [5] The standard of care ranges from amelioration of hematologic deficits with blood product transfusions and administration of recombinant growth factors to aggressive chemotherapy and stem cell transplantation for younger individuals with more aggressive disease. 6 Although generally it arises de novo with the risk increasing proportionate to age, MDS may also occur years after exposure to mutagenic chemotherapy. 1, 7 In this study we review the evolution of different classifications of MDS and the terminologies related to it over years.
In about one-third of patients, MDS can progress to a rapidly 150
Myelodysplastic syndrome is a group of clonal disorders having wide range of outcome. Its classification and concept have been changed over time with better understanding of its prognosis and clinical significance. The first standard classification was FAB classification which came in 1982. It was based on findings on peripheral blood and bone marrow. Later in 2001, WHO incorporated clinical data into it and proposed a modified classification. The 2001 WHO classification made several criteria and entities more precise based on inputs from several studies. New terminologies (e.g., refractory cytopenia with multilineage dysplasia) and new group (e.g., myelodysplastic / myeloproliferative disorder) have been introduced and group like 'refractory anemia with excess blasts in transformation' was removed. Again in 2008, in collaboration with European Association for Haematopathology and the Society for Hematopathology, as well as considering several recommendations from a group of clinical experts, WHO published a revised and updated classification. In the latest MDS classification, the clinical implications of different groups have been given more importance and also the role of cytogenetics has been re-evaluated. Several groups were again redefined (e.g., myelodysplastic syndrome -unclassified, refractory anemia with excess blasts) or eliminated (e.g., refractory cytopenia with multilineage dysplasia and ringed sideroblasts) or newly introduced (e.g., refractory cytopenia with unilineage dysplasia). Childhood MDS was considered separately as demanded by several pediatric hematologists. It was also emphasized that the diagnosis and classification of MDS mainly require identification of dysplastic morphological features, routine stains and correlation with clinical data rather than cytogenetics which may be necessary only in rare cases.
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Myelodysplastic syndrome; Refractory anemia; Ring sideroblasts; MDS classification growing cancer of bone marrow cells called acute myeloid leukemia. Because most patients do not get leukemia, MDS was previously classified as a disease of low malignant potential. Now that we have learned more about MDS, it is considered to be a form of cancer as it is a clonal disease typical of cancer. 8 
History
In 1938, the term 'refractory anaemia'(RA) was used by Rhoades and Barker to describe anaemic patients who were unresponsive to iron, vitamin B12 or folic acid. 5, 9 A subgroup of patients with RA was subsequently shown to have ring sideroblasts in the bone marrow. 9 Since then the classification and nomenclature used to describe this syndrome has changed over the last 70 years. Bjorkman 10 in 1956 noticed cases of RA that were associated with ringed sideroblasts in the bone marrow (BM) and coined the term refractory anemia with ringed sideroblasts ( RARS ). In the 1950s, it was appreciated that acute leukaemia in the elderly was often preceded by a 'pre-leukaemic' phase of peripheral blood cytopenia associated with either normal or a slightly increased percentage of bone marrow blasts. 9 Later, in 1970s terminologies like preleukemic syndrome and Hematopoietic dysplasia and subacute myeloid leukemia came up. 6 In 1982, the first standard classification was made as the French-American-British (FAB) group proposed a morphological classification based on the percentage of blasts and ringed sideroblasts in the bone marrow and the presence or absence of a peripheral blood monocytosis.
Epidemiology
MDS predominantly occurs in elderly with a median age of 70 years. 1 The overall annual incidence rate is 3-4 per 100000 which increases dramatically to 20 per 100000 and 30 per 100000 in age group above 70 and 80 years. 1, 9 Males are affected approximately 1.5 times as often as females. 11 Case control studies of possible occupational or environmental associations have provided many insights to MDS, but none other than benzene has reached a level of scientific validity.
12,13

Etiology
The etiology of most cases of primary MDS remains unknown. 9 MDS can occur as primary or de novo disorder and secondarily as therapy related disease (t-MDS).
1 Primary or de novo MDS occurs without a known history of toxic exposure and in some studies , have been linked to exposure to benzene, solvents and pesticides, and with smoking. 1, 9 However it should be remembered that dysplasia in BM can be caused secondarily by several factors which should be excluded before a diagnosis of MDS is made. It is postulated that gene polymorphism may be linked to interaction to a particular environmental factor and increased susceptibility of an individual. The t-MDS occurs with a known history of chemotherapeutic agents, most commonly alkylating agents and radiotherapy. Rarely, inherited hematological conditions (e.g., Fanconi anemia ) are associated with MDS. 1, 6 
Clinical features
Most patients present with symptoms or complication related to anemia or less commonly, neutropenia and thrombocytopenia.
1 Upto 20% cases may be detected incidentally on routine laboratory tests. 9 Lymphadenopathy and organomegaly are rare. 1, 9 A diagnosis of MDS should be considered in any individual with unexplained persistent cytopenias or monocytosis. Diabetes insipidus, acute neutrophilic dermatosis and systemic supus erythematosus (SLE) like syndromes have been reported as presenting features.
11
Diagnosis
A diagnosis of MDS should be considered in any individual with unexplained persistent cytopenias or monocytosis. The figure 1 shows the flow chart as a diagnostic approach in MDS. Careful inspection of the peripheral blood smear (PBS) and BM is necessary to document the requisite dysplastic cytologic features in one or more hematopoietic lineages. 5, 14 PBS and BM specimens should be collected prior to any definitive therapy. A standard Wright-Giemsa or similar stain is used for smears. BM biopsy ideally should be at least 1.5 cm in length and taken at right angles to the cortical bone. 15 Confirmation of dysplasia, percentage of dysplastic cells and lineages affected and in selected cases percentage of ringed sideroblasts lead to subcategorization. However, because these dysplastic findings per se may not be diagnostic of MDS, possible contributing conditions e.g., nutritional status, alcohol and drug use, occupational exposure to petrochemicals and other toxins, prior treatment with antineoplastics or radiotherapy, growth factor therapy, and risk factors for human immunodeficiency virus (HIV) must be excluded. 1, 6, 15 The preponderance of macrocytic anemia in MDS necessitates exclusion of vitamin B12 and folate deficiencies. A number of medications, including valproic acid, mycophenolate mofetil, ganciclovir, and alumtuzumab, have been associated with acquired dysplastic changes. 6 In addition, copper deficiency and zinc excess may simulate myelodysplasia. 6 Dysplastic hematopoiesis is a common finding that accompanies HIV infection. 16, 17, 18 Other than these secondary causes of marrow dysplasia , diagnostic problems can arise when marrow hypocellularity or myelofibrosis obscures the underlying disease process or when BM morphologic findings do not match with PBS and laboratory findings or blast percentage is not increased in the PBS or BM. 15,19.20 
Classifications of MDS
Dysplasia is a term that classically implies a polyclonal and, therefore, nonneoplastic process. 11 The choice of the term myelodysplasia to denote clonal (neoplastic) disorders was rather unfortunate because the term does not help in understanding the relationship of myelodysplasia to other clonal stem cell disorders. In addition, diseases such as idiopathic myelofibrosis can have all the features of "myelodysplasia" but are ignored in its classifications though it is widely used.
11
FAB classification
Several classification systems have been developed to subclassify MDS and to predict survival or transition to AML following MDS diagnosis. The first standard classification, the FAB system, was introduced in 1982 and is based on the percentage of blasts and morphological dysplastic features of blood and BM. 6, 14 According to this system, patients are diagnosed with MDS when PBS and BM findings of unexplained hematopoietic dysplasia in two or more lineages are present and/or myeloblasts are less than 30% of all BM cells.
14 FAB classification distinguishes five morphologic subtypes of MDS namely RA, RARS, RAEB, RAEB-t and CMML (Table 1) . 6, 14 However, the FAB system served as the standard for MDS classification for two decades for its easy reproducibility and provision of considerable prognostic information. 6, 21 Nonetheless, with time, the validity of the classification was questioned. 6 Drawing diagnostic distinctions among different percentage of leukemic blast cells is inconsistent with the biologic behavior of the condition. 11, 22 RA in FAB is a heterogenous group that includes patients with neutropenia and / or thrombocytopenia without anemia. 9 In RARS , the percentage of ringed sideroblasts are more than 15%. Separation of clonal RA into two categories based on whether the anemia has greater than or less than 15 percent sideroblasts is arbitrary and is not based on the pathobiology of the two variants. 11 This criteria , however was taken somewhat arbitrarily. The blasts percentage in RAEB was between 5 and 19% while in RAEB-t, it is between 20% and 29%. In general, RAEB patients have more unfavorable prognosis than RARS and RAEB-t patients follows a more indolent course than AML. 9, 23 CMML in FAB classification encompasses all cases with marrow dysplasia and more than 1000/ cumm circulating monocytes . It was recognized to be heterogeneous as it includes patients with a high monocyte count and splenomegaly more typical of a myeloproliferative (MP) disorder as well as patients with a modest monocytosis and a clinical course similar to that seen in RA or RAEB. 9 Nonetheless, in different studies over time, it was revealed that the clinical outcomes of patients assigned to the same MDS subgroup in FAB remained too variable to accurately predict survival or transformation to AML in individual patients.
21
WHO classification 2001
In 2001, the WHO proposed a revision of the FAB morphological approach and incorporated more recent clinical and genetic data. 9, 21 
Removed from MDS
The revisions included lowering the threshold for the percentage of blasts for the diagnosis of AML from 30% to 20%, thus elimination of the MDS subcategory RAEB-t. All cases with more than 20% blasts and dysplasia in more than 50% of cells in at least 2 lines have been classified as AML with multilineage dysplasia, and it may occur either de novo or following MDS or a myelodysplastic / myeloproliferative disorder (MDS/MP). 1 In addition, CMML was reclassified from the subcategory of MDS to a new subcategory of MDS/MP.
New terms
It was noted that patients with less than 5% marrow blasts had a poorer prognosis if they had multilineage dysplasia. In WHO 2001 classification, RA and RARS are confined to patients with unilineage erythroid dysplasia and new terms, RCMD and RCMD-RS have been introduced for cases with bi-or pancytopenia and dysplastic features in more than 10% of cells in two or more myeloid lineages ( Table 2,  Table 3 ).
1,6,9
RAEB has been divided into 2 subcategories viz RAEB-1 and RAEB-2 based on the observation that higher number blasts in PBS or BM denoted poorer prognoses. 1 Moreover though the significance of Auer rods within blast cells remained uncertain in classifying MDS, but any patients in whom Auer rods are seen are categorized as having RAEB-2.
9
A new subgroup of MDS unclassified (MDS-U) has also been introduced specifically for patients with unilineage, myeloid or megakaryocytic dysplasia and not as a waste basket group for inadequately investigated cases.
Similarly, another new subgroup has been introduced i.e; MDS with isolated 5q deletion, based on the uniformity of clinical and laboratory features of cases.
1 Majority of these patients were elderly women with a macrocytic anaemia, normal white cell count and a normal or raised platelet count.
1,9 BM of these patients show erythroid hypoplasia and large mono-or binuclear megakaryocytes. Progression to other group It was also described that though some patients may remain within a single WHO subgroup, others may progress through two or more subgroups during the course of their disease.
1,9
Recommendation for follow up
Patients with unilineage erythroid dysplasia, or in whom dysplasia is seen in < 10% of cells are not diagnosed as "MDS" in the absence of a clonal karyotypic abnormality. It is recommended that such patients be re-evaluated after 6 months. 15, 21 It was decided that the definition of subgroups of MDS should be more clearly redefined with precise clinical relevance and also the diagnostic role of cytogenetics and flow cytometry be clarified and re-evaluated.
15,21
The basic minimal criteria for diagnosis of MDS remains same i.e., at least 10% cells in one or more cell line must show unequivocal dysplastic features. It is again reemphasized that before a diagnosis of MDS is made, all secondary causes and congenital abnormalities should be excluded. Tables 5 and 6 we have summarized the basic approach in diagnosis based on PBS and BM findings. Table 7 shows the older terminologies of FAB and WHO 2001 and their current counterparts.
8,15
New group
The group MDS-U of WHO2001 has been re-evaluated. Refractory cytopenia with unilineage dysplasia (RCUD) has been expanded to include any unilineage dysplasia with less than 5% blasts in marrow irrespective of uni or bi-cytopenia in PBS. 8, 15, 24, 25 Thus new entities RCUD-RN and RCUD-RT have evolved. On the other hand, patients with pancytopenia and unilineage morphologic dysplasia are classified as having MDS-U, because of the uncertain clinical significance of such findings.
New definition
The definition of RAEB-1 and -2 have been redefined to emphasize blasts percentage in PBS. 15, 24, 25 RAEB-1 includes patients with 2-4% blasts in PB even if BM blasts is <5%. RAEB-2 includes patients with 5-19% blasts in PBS or 10-19% blasts in BM. So, cases of RAEB-2 may have <10% blasts in the marrow but may be diagnosed by other 2 findings; 5% to 19% blasts in the blood and/or Auer rod. 
Cytogenetics
Fifty percent of patients with a primary myelodysplastic syndrome have a normal karyotype; hence, the current classification system is still largely based on morphology. 
Flow cytometry and phenotypic abnormality
Though there are several studies demonstrating phenotypic abnormalities inflow cytometry in MDS cases, it has not been considered as "definite" diagnostic evidence due to inadequate data. 15, 24, 25 In absence of morphological and/ or cytological features, if a case has 3 or more phenotypic abnormality in flow cytometry, it can be reported as "suggestive of MDS" ( rather than "MDS" ) and should be followed up. 15, 24, 25 
MDS with unusual presentation
It was noted that some cases of MDS present with hypocellular marrow or myelofibrosis. 15, 24 It was further commented that hypocellular cases may show macrocytes in PB mimicking aplastic anemia and myelofibrosis cases may mimic AML-M7 and Idiopathic myelofibrosis (under myeloproliferative diseases). However; the clinical significance of these types of MDS are yet to be defined and so they are not categorized under any separate group. It was suggested that these cases should be subtyped as per MDS criteria with "hypoplastic" or "myelofibrosis" as prefix or suffix (e.g., RCMD with myelofibrosis). In cases with difficulty, immunohistochemical stains and cytogenetics would be helpful. 19, 28, 29 Usually mylofibrosis cases show increased CD34+ blasts and hypoplastic cases are of lower grade.
15,24
Follow up recommended
The following conditions are not classified as MDS and careful follow up is advised to monitor development of any features of MDS. 15 a. Patients with refractory cytopenia but lacking morphologic or specific cytogenic abnormality A provisional entity, "refractory cytopenia of childhood" (RCC), has been added to include children with cytopenia(s) with less than 2% blasts in the peripheral blood and less than 5% in the bone marrow and evidence of dysplasia in 2 or more lineages (Table 8) .
15 They usually present with refractory anemia , initially associated with thrombocytopenia and/or neutropenia and hypocellular BM. 15, 24, 25, 30 Sometimes, the distinction between RCC and aplastic anemia or congenital bone marrow failure syndromes may be very difficult on morphological ground and cytogenetic abnormalities may be needed.For children with 2% to 19% blasts in the blood and/or 5% to 19% in the bone marrow, the MDS subclassification should be made using the same criteria used for adults.
15
RARS-T
"Refractory anemia with ring sideroblasts and thrombocytosis" (RARS-T) does not come under MDS. (Please note that T stands for "thrombocytosis" and not "in transformation" like RAEB-t) It is a "provisional entity" kept under MDS/MP group with CMML and JMML. It includes cases with refractory anemia, thrombocytosis > 450000/cumm in PB and BM showing dyserythropoiesis, ringed sideroblasts >15% and megakaryocytes with features resembling those in primary myelofibrosis or essential thromocythemia.
15
CONCLUSION
No clinical features are specifically associated with MDS to differentiate it from other pancytopenic states. In 50% of patients, diagnosis depends on the process of elimination. Observation time and repeated BM studies may be necessary. It is to re-emphasize that diagnosis and classification of MDS mainly requires identification of dysplastic morphological features, routine stains and correlation with clinical data. Cytogenetics are necessary only in cases with inadequate morphological evidence which are rare. However very recently some studies show prognostic implications of point mutations
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